Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: IPBizPatent reform: bad for (small) business
By Lawrence B. Ebert, Esq.
It's available in the form of an amicus brief in Tafas v. Dudas:
http://docs.justia.com/cases/federal/district-courts/virginia/vaedce/1:2007cv00846/221151/235/0.pdf
See also Dr. Rick Belzer's paperwork burden analysis of the Rules in Tafas' latest submission in
http://docs.justia.com/cases/federal/district-courts/virginia/vaedce/1:2007cv00846/221151/253/0.pdf
Rick's paper is Exhibit 13, available at
http://docs.justia.com/cases/federal/district-courts/virginia/vaedce/1:2007cv00846/221151/253/13.pdf
UPDATE.
See a post at PatentHawk describing a brief filed by Tafas which includes the text:
In short, the USPTO is saying that it intends to reduce its backlog by restricting and/or denying patent applicants the ability to make filings (e.g., continuations and multiple claims) expressly contemplated by various provisions of the Patent Act. It is only a small exaggeration to say the USPTO?s approach would be akin to the manager of an amusement park seeking to reduce lines for rides by not admitting anyone to the park. Only applying the most extreme bootleg logic could such an approach be characterized as reasonably calculated at ?expediting? or ?facilitating? a reduction in amusement park lines. The same is true here.
IPBiz notes a variant on this amusement park theme from an episode in South Park
IPBiz notes the Tafas brief also discusses re-work:
The USPTO has continually argued that continuation applications are inappropriately adding to its backlog as they comprise nothing more than ?rework.? (See Testimony of Jon W. Dudas before the subcommittee on Intellectual Property Committee on the Judiciary April 21, 2005 (p. 9), Ex. 26 to Rueda Declaration dated December 20, 2007 (?Rueda Decl.?). Nonetheless, the USPTO cites no evidence to support this assertion in the record other than rehashing Mr. Dudas? own earlier unsupported assertion, which type of ipse dixit statement does not become fact through mere repetition.
Full post as published by IPBiz on January 25, 2008 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Texas, USA
alleging the Medical Malpractice and Tort Reform Act of 2003 violates several provisions of the Constitution.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Express Scripts Inc.
Over $9.5 million payout in deceptive business practices lawsuit.
FedEx
Ground Business Model Wins Class Action in Washington

White House Opposes Patent Reform Acts Limit on Damage Calculations
Vote on Patent Reform Delayed; Senators Remain Optimistic
How Patent Reform is like a Sombrero








